Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BioXcel Therapeutics, Inc.

https://www.bioxceltherapeutics.com/

Latest From BioXcel Therapeutics, Inc.

Sosei Heptares Turns To AI In GPCR-Focused Drug Discovery Pact

Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure-based drug design and early development capabilities with InveniAI's already validated AI-based platform, its head of new target identification tells Scrip.

Companies Deals

Finance Watch: Five Biopharma IPOs Bring US Total To 60 In 2021

Public Company Edition: Almost halfway through the year, initial public offerings equal nearly three-quarters of the 2020 total. Also, Pardes is one of four new SPAC mergers; HUTCHMED launched an IPO in Hong Kong; and Zentalis, Theravance and BioXcel launched follow-on offerings.

Financing Growth

Breakthrough Therapy Designations At US FDA Stay Sluggish In 2021

With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.

Review Pathway Drug Review

Keeping Track: Recent NDA Submissions Range From Acute Agitation To Von Hippel-Lindau Disease

News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker

US FDA Performance Tracker Drug Review
See All

Company Information

  • Industry
  • Biotechnology
  • Digital Health
  • Pharmaceuticals
UsernamePublicRestriction

Register